Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rakesh Dixit

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Reproductive Toxicology (Elmsford, N.Y.)|September 17, 2017
Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspringSimone M Nicholson, Gianluca Carlesso, Lily I Cheng, et al.
Mabs|March 6, 2019
Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimerJason B White, Ryan Fleming, Luke Masterson, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 22, 2016
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokineticsPamela Thompson, Ryan Fleming, Binyam Bezabeh, et al.
Critical Reviews in Toxicology|October 25, 2007
Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selectionLorenz R Rhomberg, Karl Baetcke, Jerry Blancato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2017
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug ConjugatesMary Jane Masson Hinrichs, Pauline M Ryan, Bo Zheng, et al.
Oncotarget|May 26, 2018
Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancerEmily E Bosco, R James Christie, Rosa Carrasco, et al.
Cancer Cell|January 15, 2016
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyJohn Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Cancer Cell|June 12, 2019
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyJohn Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Pharmaceutical Research|April 23, 2005
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference reportJean W Lee, Russ S Weiner, Jeff M Sailstad, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Reproductive Toxicology (Elmsford, N.Y.)|September 17, 2017
Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspringSimone M Nicholson, Gianluca Carlesso, Lily I Cheng, et al.
Mabs|March 6, 2019
Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimerJason B White, Ryan Fleming, Luke Masterson, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 22, 2016
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokineticsPamela Thompson, Ryan Fleming, Binyam Bezabeh, et al.
Critical Reviews in Toxicology|October 25, 2007
Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selectionLorenz R Rhomberg, Karl Baetcke, Jerry Blancato, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2017
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug ConjugatesMary Jane Masson Hinrichs, Pauline M Ryan, Bo Zheng, et al.
Oncotarget|May 26, 2018
Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancerEmily E Bosco, R James Christie, Rosa Carrasco, et al.
Cancer Cell|January 15, 2016
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyJohn Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Cancer Cell|June 12, 2019
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyJohn Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Pharmaceutical Research|April 23, 2005
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference reportJean W Lee, Russ S Weiner, Jeff M Sailstad, et al.
Pageof 4